Prevalence and Persistence of Maternal Dengue Neutralizing Antibodies in Infants From Central and Southern Thailand: A Retrospective Cohort Study

Abstract

Understanding maternal dengue virus (DENV) neutralizing antibody kinetics in infants remains timely to develop a safe and effective childhood immunization. This retrospective study evaluated the prevalence and persistence of maternal antibody titers against DENV serotypes 1 to 4 in 139 Thai infants at 2, 6, and 7 months of age, using serum samples collected in a vaccination trial (http://clinicaltrials.gov; NCT00197275). Neutralizing antibodies against all 4 DENV serotypes were detected in 87.8% and 22.9% of infants at 2 and 7 months, respectively. At 2 months, DENV-4 neutralizing antibody geometric mean titers were notably lower (80) compared with DENV-1 to DENV-3 (277-471). Our results corroborate previous findings that DENV-1 to DENV-4 maternal antibodies persist at 7 months despite titers decrease from 2 months onwards. As persisting maternal antibodies may inhibit immune responses in DENV-vaccinated infants, a comprehensive understanding of DENV antibody kinetics is required in the perspective of vaccine development for infants.

Keywords

dengue virus immunization infants maternal neutralizing antibodies persistence prevalence

Get full access to this article

View all access options for this article.

References

Guzman

Harris

. Dengue. Lancet. 2015;385:453-465.

Clapham

Cummings

DAT

Johansson

. Immune status alters the probability of apparent illness due to dengue virus infection: evidence from a pooled analysis across multiple cohort and cluster studies. PLoS Negl Trop Dis. 2017;11:e0005926.

Bhatt

Gething

Brady

et al . The global distribution and burden of dengue. Nature. 2013;496:504-507.

Limkittikul

Brett

L’Azou

. Epidemiological trends of dengue disease in Thailand (2000-2011): a systematic literature review. PLoS Negl Trop Dis. 2014;8:e3241.

Vongpunsawad

Intharasongkroh

Thongmee

Poovorawan

. Seroprevalence of antibodies to dengue and chikungunya viruses in Thailand. PLoS One. 2017;12:e0180560.

World Health Organization. Immunization, vaccines and biologicals. Questions and answers on dengue vaccines. https://www.who.int/immunization/research/development/dengue_q_and_a/en/. Accessed February 7, 2019.

Chau

Anders

Lienle

et al . Clinical and virological features of dengue in Vietnamese infants. PLoS Negl Trop Dis. 2010;4:e657.

Zhang

Tan

et al . First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog. 2014;10:e1004031.

Katzelnick

Gresh

Halloran

et al . Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358:929-932.

10.

Edwards

. Maternal antibodies and infant immune responses to vaccines. Vaccine. 2015;33:6469-6472.

11.

Niewiesk

. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol. 2014;5:446.

12.

Pengsaa

Limkittikul

Luxemburger

et al . Age-specific prevalence of dengue antibodies in Bangkok infants and children. Pediatr Infect Dis J. 2008;27:461-463.

13.

Pengsaa

Luxemburger

Sabchareon

et al . Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in Thai children. J Infect Dis. 2006;194:1570-1576.

14.

Roehrig

Hombach

Barrett

. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008;21:123-132.

15.

Srikiatkhachorn

Yoon

. Immune correlates for dengue vaccine development. Expert Rev Vaccines. 2016;15:455-465.

16.

van Panhuis

Luxemburger

Pengsaa

et al . Decay and persistence of maternal dengue antibodies among infants in Bangkok. Am J Trop Med Hyg. 2011;85:355-362.

17.

Watanaveeradej

Endy

Samakoses

et al . Transplacentally transferred maternal-infant antibodies to dengue virus. Am J Trop Med Hyg. 2003;69:123-128.

18.

Libraty

Acosta

Tallo

et al . A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 2009;6:e1000171.

19.

Clapham

Cummings

Nisalak

et al . Epidemiology of infant dengue cases illuminates serotype-specificity in the interaction between immunity and disease, and changes in transmission dynamics. PLoS Negl Trop Dis. 2015;9:e0004262.